Financials Mankind Pharma Limited

Equities

MANKIND

INE634S01028

Pharmaceuticals

Delayed NSE India S.E. Other stock markets 03:32:38 22/05/2024 pm IST			5-day change	1st Jan Change
2,107 ^INR	+1.07%		-3.82%	+6.29%

16/05	Transcript : Mankind Pharma Limited, Q4 2024 Earnings Call, May 16, 2024
16/05	Mankind Pharma's Consolidated Profit Jumps in Fiscal Q4	MT

Valuation

Fiscal Period: March	2024	2025	2026
Capitalization ¹	8,35,284	-	-
Enterprise Value (EV) ¹	9,21,654	7,99,625	7,77,248
P/E ratio	48.3 x	38.1 x	32 x
Yield	0.33%	0.27%	0.54%
Capitalization / Revenue	8.92 x	7.2 x	6.34 x
EV / Revenue	8.92 x	6.89 x	5.9 x
EV / EBITDA	36.4 x	27.1 x	22.6 x
EV / FCF	54.4 x	43.3 x	35 x
FCF Yield	1.84%	2.31%	2.85%
Price to Book	9.03 x	7.2 x	5.97 x
Nbr of stocks (in thousands)	4,00,635	-	-
Reference price ²	2,085	2,085	2,085
Announcement Date	15/05/24	-	-

¹INR in Million²INR

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March	2022	2023	2024	2025	2026
Net sales ¹	-	87,494	1,03,348	1,16,034	1,31,785
EBITDA ¹	-	19,006	25,351	29,499	34,387
EBIT ¹	-	15,747	21,368	25,356	29,843
Operating Margin	-	18%	20.68%	21.85%	22.64%
Earnings before Tax (EBT) ¹	-	16,712	23,994	27,760	32,958
Net income ¹	14,335	12,819	19,129	21,939	26,155
Net margin	-	14.65%	18.51%	18.91%	19.85%
EPS ²	35.78	32.00	47.68	54.74	65.24
Free Cash Flow ¹	-	10,243	14,885	18,467	22,188
FCF margin	-	11.71%	14.44%	15.91%	16.84%
FCF Conversion (EBITDA)	-	53.89%	59.69%	62.6%	64.52%
FCF Conversion (Net income)	-	79.91%	81.35%	84.17%	84.83%
Dividend per Share ²	-	-	6.850	5.625	11.22
Announcement Date	01/08/22	30/05/23	15/05/24	-	-

¹INR in Million²INR

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March	2024 Q1	2024 Q2	2024 Q3	2024 Q4
Net sales ¹	25,786	26,998	24,214	24,228
EBITDA ¹	6,548	6,987	5,822	5,585
EBIT ¹	5,675	5,706	4,347	4,155
Operating Margin	22.01%	21.13%	17.95%	17.15%
Earnings before Tax (EBT) ¹	6,245	6,229	4,984	4,776
Net income ¹	4,869	5,176	4,194	3,823
Net margin	18.88%	19.17%	17.32%	15.78%
EPS ²	12.14	11.00	9.867	9.350
Dividend per Share	-	-	-	-
Announcement Date	02/08/23	-	-	-

¹INR in Million²INR

Estimates

Balance Sheet Analysis

Fiscal Period: March	2022	2023	2024	2025	2026
Net Debt ¹	-	-	-	-	-
Net Cash position ¹	-	-	25,253	35,660	58,037
Leverage (Debt/EBITDA)	-	-	-	-	-
Free Cash Flow ¹	-	10,243	14,885	18,467	22,188
ROE (net income / shareholders' equity)	-	18.9%	21.3%	21.3%	20.9%
ROA (Net income/ Total Assets)	-	13.6%	17.4%	18.5%	18%
Assets ¹	-	94,317	1,05,403	1,18,679	1,45,261
Book Value Per Share ²	-	186.0	231.0	290.0	349.0
Cash Flow per Share ²	-	45.30	54.90	65.40	76.70
Capex ¹	-	7,890	4,882	4,907	5,235
Capex / Sales	-	9.02%	4.73%	4.23%	3.97%
Announcement Date	01/08/22	30/05/23	15/05/24	-	-

¹INR in Million²INR

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Mankind Pharma Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2,085 INR

Average target price

2,227 INR

Spread / Average Target

+6.83%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MANKIND PHARMA LIMITED	+6.29%	10.03B
ELI LILLY AND COMPANY	+37.78%	723B
NOVO NORDISK A/S	+31.60%	598B
JOHNSON & JOHNSON	-3.51%	364B
MERCK & CO., INC.	+19.94%	331B
ABBVIE INC.	+5.14%	288B
ASTRAZENECA PLC	+16.53%	244B
ROCHE HOLDING AG	-4.42%	208B
NOVARTIS AG	+10.26%	210B
AMGEN INC.	+9.32%	169B

Other Pharmaceuticals